These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 20414037)
1. [Successful desensitization protocol for patients with hypersensitivity reactions caused by carboplatin]. Nishio S; Koyanagi T; Miyabe K; Kuromatsu H Gan To Kagaku Ryoho; 2010 Apr; 37(4):731-3. PubMed ID: 20414037 [TBL] [Abstract][Full Text] [Related]
2. [Successful desensitization using cisplatin after carboplatin-associated hypersensitivity reactions in 3 cases with recurrent ovarian carcinoma]. Hosaka M; Ebina Y; Moriwaki M; Hara Y; Araki N; Todo Y; Takeda M; Watari H; Sakuragi N Gan To Kagaku Ryoho; 2007 Sep; 34(9):1505-8. PubMed ID: 17876157 [TBL] [Abstract][Full Text] [Related]
3. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154 [TBL] [Abstract][Full Text] [Related]
5. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Lee CW; Matulonis UA; Castells MC Gynecol Oncol; 2004 Nov; 95(2):370-6. PubMed ID: 15491759 [TBL] [Abstract][Full Text] [Related]
6. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Lee CW; Matulonis UA; Castells MC Gynecol Oncol; 2005 Nov; 99(2):393-9. PubMed ID: 16054201 [TBL] [Abstract][Full Text] [Related]
7. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer. Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107 [TBL] [Abstract][Full Text] [Related]
8. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study. Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224 [TBL] [Abstract][Full Text] [Related]
9. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma. Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219 [TBL] [Abstract][Full Text] [Related]
11. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Bolis G; Scarfone G; Giardina G; Villa A; Mangili G; Melpignano M; Presti M; Tateo S; Franchi M; Parazzini F; Gynecol Oncol; 2001 Apr; 81(1):3-9. PubMed ID: 11277642 [TBL] [Abstract][Full Text] [Related]
12. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Broome CB; Schiff RI; Friedman HS Med Pediatr Oncol; 1996 Feb; 26(2):105-10. PubMed ID: 8531847 [TBL] [Abstract][Full Text] [Related]
14. One year maintenance of carboplatin in patients with epithelial ovarian cancer--a phase II study. Safra T; Kovner F; Barak N; Inbar MJ; Ron IG Isr Med Assoc J; 2006 Jan; 8(1):27-9. PubMed ID: 16450747 [TBL] [Abstract][Full Text] [Related]
15. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. Hesterberg PE; Banerji A; Oren E; Penson RT; Krasner CN; Seiden MV; Wong JT J Allergy Clin Immunol; 2009 Jun; 123(6):1262-7.e1. PubMed ID: 19501233 [TBL] [Abstract][Full Text] [Related]
16. Successful carboplatin desensitization in patients with proven carboplatin allergy. Confino-Cohen R; Fishman A; Altaras M; Goldberg A Cancer; 2005 Aug; 104(3):640-3. PubMed ID: 15977213 [TBL] [Abstract][Full Text] [Related]
17. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222 [TBL] [Abstract][Full Text] [Related]
18. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience. Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218 [TBL] [Abstract][Full Text] [Related]
19. Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful? Syrigou E; Makrilia N; Vassias A; Nikolaidis I; Xyla V; Manolopoulos L; Syrigos K Anticancer Drugs; 2010 Mar; 21(3):333-8. PubMed ID: 20038831 [TBL] [Abstract][Full Text] [Related]